

## CLAIMS

1. A method for examining kidney disease, which comprises detecting a fatty acid binding protein contained in a specimen collected from a mammal other than rodents, said fatty acid binding protein being derived from kidney tissue.

2. The examination method according to claim 1, wherein the fatty acid binding protein being derived from kidney tissue is a liver-type fatty acid binding protein.

3. The examination method according to claim 1, wherein the kidney tissue is tissue from the proximal tubule of the kidney.

4. The examination method according to claim 1, wherein the specimen is kidney tissue or urine.

5. The examination method according to claim 1, wherein the mammal other than rodents is human.

6. The examination method according to claim 1, which further comprises a process for comparing the test result with that of a control specimen collected from an animal having normal kidney tissue.

7. The examination method according to claim 1, wherein the detection of the fatty acid binding protein is carried out using an antibody specifically binding to said fatty acid binding protein.

8. The examination method according to claim 7,  
wherein the antibody specifically binding to the fatty acid  
binding protein is an antibody specifically binding to a  
liver-type fatty acid binding protein.

*Sub A2* 5  
C2

9. The examination method according to claim 8,  
wherein the antibody specifically binding to the fatty acid  
binding protein is an antibody that substantially does not  
cross-react with a heart muscle-type fatty acid binding  
protein.

10 10. A method for examining kidney disease excluding  
 $\alpha_{2u}$ -globulin nephropathy of rodent, which comprises  
detecting an  $\alpha_{2u}$ -globulin or a fatty acid binding protein  
contained in a specimen collected from a rodent selected  
from rat and mouse, and further determining the decrease in  
15 the amount thereof with comparing it with that of a  
specimen from a normal animal, said fatty acid binding  
protein being derived from kidney tissue.

20 11. The examination method according to claim 10,  
wherein the fatty acid binding protein is a kidney-type  
fatty acid binding protein.

12. The examination method according to claim 10,  
wherein the specimen is kidney tissue, urine or blood.

13. The examination method according to claim 10,  
wherein the kidney diseases are an anti-GMB nephritis model.

14. A reagent or kit for examination, which is used

0  
5  
7  
8  
9  
E  
0  
5  
2  
6  
0  
0

*Sub A3* 35  
C3

in the examination method according to any one of claims 1-13.

15. The reagent or kit for examination according to  
claim 14, which contains an antibody specifically binding  
5 to a fatty acid binding protein.

add A14  
add C6

09578693 - 052600